BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19802016)

  • 21. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
    Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
    Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
    Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
    Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
    Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
    Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
    J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
    Yang BF; Xiao C; Li H; Yang SJ
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
    Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
    Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
    Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation-induced degradation of FLIP(L) is mediated via the phosphatidylinositol 3-kinase/Akt signaling pathway in macrophages.
    Shi B; Tran T; Sobkoviak R; Pope RM
    J Biol Chem; 2009 May; 284(21):14513-23. PubMed ID: 19339247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
    Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
    Le Clorennec C; Lazrek Y; Dubreuil O; Sampaio C; Larbouret C; Lanotte R; Poul MA; Barret JM; Prost JF; Pèlegrin A; Chardès T
    Cell Commun Signal; 2019 Aug; 17(1):106. PubMed ID: 31443721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein.
    Xiao CW; Yan X; Li Y; Reddy SA; Tsang BK
    Endocrinology; 2003 Feb; 144(2):623-30. PubMed ID: 12538625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL; Allison JM; Shimizu Y; ElShamy WM
    Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
    FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.